Use of Medical Cannabis in Patients with Gilles de la Tourette's Syndrome in a Real-World Setting
Objective: Tourette's syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics and other comorbidities. Clinical recommendations for the use of medical cannabis are established, yet further guidance is needed. The aim of this study was to describe the experience of patients with TS with medical cannabis. Materials and Methods: TS patients were recruited from a registry of patients ("Tikun Olam" company). Questionnaires were answered before and after 6 months of treatment. Patients were divided into two groups: (A) patients who responded and (B) patients who did not respond to the follow-up questionnaire. In group A, an analysis was made to evaluate the presence and frequency of motor and vocal tics. The patients' general mood, employment status, quality of life, and comorbidities were also included in the analysis. Results: Seventy patients were identified. The tetrahydrocannabinol and cannabidiol mean daily dose was 123 and 50.5 mg, respectively. In group A, a statistically significant improvement was identified in quality of life (p<0.005), employment status (p=0.027), and in the reduction of the number of medications (p<0.005). Sixty-seven percent and 89% of patients with obsessive-compulsive disorder and anxiety comorbidities, respectively, reported an improvement. No statistically significant improvement was identified in motor tics (p=0.375), vocal tics (p>0.999), tics frequency (p=0.062), or general mood (p=0.129). The most frequent adverse effects were dizziness (n=4) and increased appetite (n=3). Conclusion: Subjective reports from TS patients suggest that medical cannabis may improve their quality of life and comorbidities. More studies are needed to evaluate the efficacy and safety of medical cannabis. Registry in the MOH: https://www.moh.gov.sg/ (Trial number: 0185-19-ASF).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Cannabis and cannabinoid research - 9(2024), 1 vom: 01. Feb., Seite 293-299 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barchel, Dana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/can.2022.0112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348567510 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348567510 | ||
| 003 | DE-627 | ||
| 005 | 20240319232101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/can.2022.0112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM348567510 | ||
| 035 | |a (NLM)36342913 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barchel, Dana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of Medical Cannabis in Patients with Gilles de la Tourette's Syndrome in a Real-World Setting |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: Tourette's syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics and other comorbidities. Clinical recommendations for the use of medical cannabis are established, yet further guidance is needed. The aim of this study was to describe the experience of patients with TS with medical cannabis. Materials and Methods: TS patients were recruited from a registry of patients ("Tikun Olam" company). Questionnaires were answered before and after 6 months of treatment. Patients were divided into two groups: (A) patients who responded and (B) patients who did not respond to the follow-up questionnaire. In group A, an analysis was made to evaluate the presence and frequency of motor and vocal tics. The patients' general mood, employment status, quality of life, and comorbidities were also included in the analysis. Results: Seventy patients were identified. The tetrahydrocannabinol and cannabidiol mean daily dose was 123 and 50.5 mg, respectively. In group A, a statistically significant improvement was identified in quality of life (p<0.005), employment status (p=0.027), and in the reduction of the number of medications (p<0.005). Sixty-seven percent and 89% of patients with obsessive-compulsive disorder and anxiety comorbidities, respectively, reported an improvement. No statistically significant improvement was identified in motor tics (p=0.375), vocal tics (p>0.999), tics frequency (p=0.062), or general mood (p=0.129). The most frequent adverse effects were dizziness (n=4) and increased appetite (n=3). Conclusion: Subjective reports from TS patients suggest that medical cannabis may improve their quality of life and comorbidities. More studies are needed to evaluate the efficacy and safety of medical cannabis. Registry in the MOH: https://www.moh.gov.sg/ (Trial number: 0185-19-ASF) | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Tourette's syndrome | |
| 650 | 4 | |a medical cannabis | |
| 650 | 4 | |a motor and vocal tics | |
| 650 | 4 | |a obsessive compulsive disorder | |
| 650 | 4 | |a quality of life | |
| 650 | 7 | |a Medical Marijuana |2 NLM | |
| 700 | 1 | |a Stolar, Orit |e verfasserin |4 aut | |
| 700 | 1 | |a Ziv-Baran, Tomer |e verfasserin |4 aut | |
| 700 | 1 | |a Gueta, Itai |e verfasserin |4 aut | |
| 700 | 1 | |a Berkovitch, Matitiahu |e verfasserin |4 aut | |
| 700 | 1 | |a Kohn, Elkana |e verfasserin |4 aut | |
| 700 | 1 | |a Bar-Lev Schleider, Lihi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cannabis and cannabinoid research |d 2016 |g 9(2024), 1 vom: 01. Feb., Seite 293-299 |w (DE-627)NLM262402297 |x 2378-8763 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:1 |g day:01 |g month:02 |g pages:293-299 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/can.2022.0112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 1 |b 01 |c 02 |h 293-299 | ||